Moderna and Merck have announced promising results from a Phase 2b clinical trial involving their investigational individualized neoantigen therapy, mRNA-4157 (V940), in combination with Merck's immunotherapy drug KEYTRUDA (pembrolizumab). The trial, known as KEYNOTE-942, included patients with high-risk stage III/IV melanoma following complete resection and demonstrated a sustained improvement in recurrence-free survival and distant metastasis-free survival compared to KEYTRUDA alone. Over a period of 34.9 months, the combination therapy reduced the risk of recurrence or death by 49% and the risk of distant metastasis by 62%, with a hazard ratio for recurrence-free survival of 0.51 and distant metastasis-free survival of 0.38. These findings were presented at the ASCO24 conference, and the companies have indicated that a Phase 3 trial is ongoing. The positive results have led to a rise in the shares of both Moderna and Merck.
More below on 3 year update on Moderna/Merck phase 2 melanoma clinical trial. Phase 3 is ongoing #ASCO24 https://t.co/uzeLPW720U
Below is 3 year update #ASCO24 presentation re: Phase 2 trial of Moderna's investigational mRNA-4157 (V940) in combo w/Merck's immunooncology drug Keytruda in patients with resected high-risk melanoma (stage III/IV): "continued to demonstrate a clinically meaningful & durable… https://t.co/ybINJTxNRK
Moderna and Merck announced promising results from a clinical trial testing a combined treatment of an mRNA vaccine and immunotherapy for skin cancer. https://t.co/FJUxpcxUkl
📢@moderna_tx and @Merck announce 3-year data for mRNA-4157 (V940) in combination with KEYTRUDA(R) (pembrolizumab) in study of patients with high-risk stage III/IV melanoma. #FlagshipFounded https://t.co/buE0IWcv9H
Moderna, Merck shares rise as combined melanoma therapy shows improved survival rate https://t.co/cL1uXNhHt5 https://t.co/WlLZaZEWne
Last week, FDA approval of Moderna’s RSV vaccine for those over 60. Today, a joint announcement with Merck that that mRNA-4157 Phase 2b study over 34.9 months “reduced the risk of recurrence or death by 49% and the rest of distant metastasis by 62% compared to Keytruda alone in… https://t.co/81MsnVYOZx
Very exciting- 3 year update from Dr Jeff Weber on KEYNOTE-942 (adjuvant phase 2 mRNA vaccine+pembro). Updated HR for RFS 0.51, DMFS 0.38. OS follow up and translational analysis ongoing. Phase 3 ongoing! #melanoma #ASCO24 @OncoAlert https://t.co/tkfOLQ7kxM
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer https://t.co/uF8jsOP7zu
Moderna and @Merck today announced that mRNA-4157 (V940), an investigational individualized neoantigen therapy, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, demonstrated sustained improvement in recurrence-free survival and distant metastasis-free survival compared… https://t.co/RnA2s2IIru
We’re pleased to share late-breaking data with @moderna_tx at #ASCO24 for our investigational individualized neoantigen therapy in combination with immunotherapy for #melanoma, as we continue to advance our oncology pipeline. Learn more here: https://t.co/7Ab7oXwYg7 https://t.co/x1okg7GLfu
$MRNA $MRK Announce 3-Year Data For mRNA-4157 in Combination With KEYTRUDA Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection…